FDA
-
-
-
-
-
-
-
Korro Reports Second Quarter 2025 Financial Results and Provides Business Updates
-
-
-
-
-
-
-
KRRO-110 Receives Orphan Drug Designation from U.S. FDA for Alpha-1 Antitrypsin Deficiency
-
-
-
-
-
322,248 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

